Coherus Oncology, Inc..
CHRS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Coherus BioSciences, Inc., is a commercial-stage biopharmaceutical company, which engages in the research, development, and commercialization of biosimilar therapeutics. The company focuses on oncology and immunology. Its marketed products include UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulas...Show More
Better Health for All
0
No specific, concrete data points or quantitative evidence were found across the provided articles to assess Coherus Oncology, Inc. against the 'Better Health for All' ethical value. The articles either resulted in errors (404 or application errors) or were technical documents that explicitly stated a lack of quantitative data, regulatory actions, certifications, awards, or industry benchmarks relevant to the requested metrics.
1
Fair Money & Economic Opportunity
0
Coherus BioSciences is a biopharmaceutical company focused on developing and commercializing biosimilar therapeutics. The provided articles detail its patient assistance programs for oncology products, which offer co-pay assistance and patient assistance programs for eligible individuals, including those with income at or below 500% of the Federal Poverty Level.
1
However, the ethical value 'Fair Money & Economic Opportunity' and its associated KPIs are designed to assess companies involved in lending, insuring, moving, or storing money. As Coherus BioSciences does not operate in the financial services sector and does not offer financial products or services such as loans, insurance, or deposit accounts, none of the KPIs in the rubric are applicable to its business activities. Therefore, no specific data points could be mapped to the provided KPIs.
Fair Pay & Worker Respect
40
In 2019, the company's CEO to median employee pay ratio was 13.8:1.
1
The CEO's total compensation was $5,361,707, while the median employee's compensation was $388,857.
2
Fair Trade & Ethical Sourcing
0
No specific, concrete data points were found in the provided articles regarding Coherus Oncology, Inc.'s fair trade certifications, supplier audit frequency, forced or child labor incidents in its supply chain, traceability coverage, remediation speed for supplier violations, ethical clauses in supplier contracts, share of high-risk materials, or supplier diversity spend.
1
The articles primarily discuss internal corporate governance and healthcare compliance programs, not supply chain or sourcing practices relevant to the defined KPIs.
2
Honest & Fair Business
-30
Coherus Oncology, Inc. has a Code of Business Conduct and Ethics, amended on June 3, 2025, which applies to all employees, officers, and directors.
1
It includes a toll-free compliance hotline and an online portal for anonymous reporting, and explicitly states that retaliation for good faith reports will not be tolerated.
2
Annual healthcare compliance training is required for all employees involved in commercial activities.
3
The company recasted certain financial information in its 2024 Form 10-K to provide a retrospective discontinued operations presentation for the years ended December 31, 2024 and 2023.
4
The Board of Directors has determined that approximately 75% of its directors are independent, with two directors not qualifying due to employment or executive search services provided to the company.
5
The company states it has instituted and maintained policies and procedures designed to promote and achieve compliance with anti-corruption laws, including the U.S. Foreign Corrupt Practices Act of 1977 and the U.K. Bribery Act 2010, and declares substantial compliance with its Comprehensive Healthcare Compliance Program as of July 2025.
6
Kind to Animals
-70
Coherus Oncology, Inc. has significant involvement in animal testing, utilizing preclinical laboratory and animal tests, including toxicity assessments, for its biosimilar products as part of the FDA approval process.
1
The company has no explicit corporate policy stated regarding animal testing.
2
There is no information indicating the company employs non-animal testing methods for product safety and efficacy.
3
No War, No Weapons
0
Coherus Oncology, Inc. is a biopharmaceutical company focused on oncology and immunology.
1
The provided articles consistently state that the company's focus is on oncology, developing and commercializing biosimilar therapeutics for cancer. There is no evidence in the articles to suggest any involvement in arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, or any other defense-related activities. Several KPIs are explicitly noted as 'Not applicable; the company is focused on oncology,' indicating no defense or arms-related activities in its core business.
2
One article mentions a 'Responsible Minerals Policy' but this is for 'Coherent Corp.', a different entity, and not applicable to Coherus Oncology, Inc.
3
Planet-Friendly Business
0
No evidence available to assess Coherus Oncology, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
The company has no reported cultural appropriation incidents across the provided articles.
1
No other specific, concrete data points were found for any other KPIs related to Respect for Cultures & Communities.
2
Safe & Smart Tech
0
No evidence available to assess Coherus Oncology, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence available to assess Coherus Oncology, Inc. on Zero Waste & Sustainable Products.